These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32112204)

  • 1. Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.
    Peng XV; Ayyagari R; Lubwama R; Shi L; Price-Haywood EG; Hollander P; Fonseca V
    Diabetes Ther; 2020 Apr; 11(4):995-1005. PubMed ID: 32112204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
    Peng XV; McCrimmon RJ; Shepherd L; Boss A; Lubwama R; Dex T; Skolnik N; Ji L; Avogaro A; Blonde L
    Diabetes Ther; 2020 Nov; 11(11):2629-2645. PubMed ID: 32902774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
    Rosenstock J; Ampudia-Blasco FJ; Lubwama R; Peng XV; Boss A; Shi L; Fonseca V
    Diabetes Obes Metab; 2020 Dec; 22(12):2295-2304. PubMed ID: 32729183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
    Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
    Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
    Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
    Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
    Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
    Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
    Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 12. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
    Blonde L; Meneghini L; Peng XV; Boss A; Rhee K; Shaunik A; Kumar S; Balodi S; Brulle-Wohlhueter C; McCrimmon RJ
    Diabetes Ther; 2018 Jun; 9(3):1347-1358. PubMed ID: 29600507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
    Abusnana S; Al Awadi F; Aly H; Bashier A; Kumar Dhanwal D; Halasa T; Jallo M; Medina J; Singhal S
    Diabetes Res Clin Pract; 2023 Feb; 196():110183. PubMed ID: 36436550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
    Candido R; Nicolucci A; Larosa M; Rossi MC; Napoli R;
    Nutr Metab Cardiovasc Dis; 2023 Nov; 33(11):2294-2305. PubMed ID: 37679243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
    Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
    Bailey TS; Gill J; Jones S M; Shenoy L; Nicholls C; Westerbacka J
    Diabetes Obes Metab; 2022 Aug; 24(8):1617-1622. PubMed ID: 35491520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.